Roche's Trastuzumab Emtansine Has Positive Results Against Metastatic Breast Cancer

[News]

Roche released an announcement today in regards to its phase three trial called EMILIA. The program compared performance of its new drug Trastuzumab Emtansine against standard treatments for HER2-positive Metastatic Breast Cancer that use lapatinib plus Xeloda® (capecitabine). Patients were enrolled in the study having previously received Herceptin® and ataxane (chemotherapy)...

More... (http://www.medicalnewstoday.com/articles/243609.php)